Articles On Neuren Pharmaceuticals (ASX:NEU)

What’s in a name? Not much, according to the CEO of the now cashed-up Percheron, Dr James Garner. Formerly known as Antisense Therapeutics, the rare disease specialist changed its name to Percheron in January. Percheron means ‘draught horse...

The ASX200 closed up around 0.9% at 8,355 points after hitting a new record of 8,384 points just before September jobs data was released this morning. The better than expected unemployment rate of 4.1% saw markets reduce the odds of an R...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.7% to 8,345.3 points. Four ASX shares that are rising more than most today are listed below....

The Australian share market is rebounding nicely on Thursday following a solid session on Wall Street overnight. Two ASX 200 shares that are contributing are listed below. Here's why they are pushing higher today: Neuren Pharmaceuticals Lt...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

  Jon Pilcher – Managing Director & CEO – Neuren Pharmaceuticals Limited (ASX:NEU) is developing new therapies for highly debilitating neurodevelopmental disorders that emerge in early childhood.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is fighting hard to get into positive territory but has fallen a touch short. The benchmark index is down slightly to 8,203.4 points. Four ASX shares that are falling more than most...

The ASX200 has been up around 0.6% of a percent at 8,198 points in early afternoon trade. The labour day holiday in some states has seen the bourse trading in lower volumes, as investors continue to digest the unfolding conflict in the M...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.5% to 8,188.4 points. Four ASX shares that are rising more than most today are listed below....

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a strong start to the week. In morning trade, the ASX 200 healthcare stock is up over 4% to $14.63. Why is this ASX 200 healthcare stock charging higher? The catalyst for this gain has...

Neuren Pharmaceuticals (ASX:NEU) has said it’s received a “positive” response from the FDA regarding a potential approval for its Phase 3 trial to treat children with Phelan-McDermid Syndrome (PMS.) Using Neuren’s in-house drug candidate...

If you are looking for some new additions to your portfolio in October, then the ASX shares listed below could be worth a closer look. They have both been named as favoured shares by Bell Potter for the month ahead. The broker notes that...

It was a bouncy, yet overall positive day for ASX shares this Friday to end the trading week. By the time trading wrapped by, the S&P/ASX 200 Index (ASX: XJO) had inched 0.1% higher, leaving...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

The S&P/ASX 200 Index (ASX: XJO) may be at a record high, but that doesn't mean there aren't any great value shares out there. For example, the two ASX 200 shares listed below have been named as strong buys by brokers and tipped to ris...

When I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lifting team performance was to replace the coach – a ploy that works about as often as it doesn’t. Back then, Rick Valencia had just replaced...

Are you wanting big returns for your portfolio? Then look no further! That's because the ASX 200 shares listed below have been named as buys and tipped to rise by ~40%+ from current levels. Here's what analysts are predicting from them: Ne...

The S&P/ASX 200 Index (ASX: XJO) ended the trading week on a high this Friday. Literally so, with the index once again resetting its intraday trading re...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

4DMedical could replicate Pro Medicus’ US success Its new tech could revolutionise lung disease diagnostics  Potential Philips deal drives optimism for 4DX Stockhead’s markets guru Eddy Sunarto brings you the latest updates from leading A...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck Welcome to the FNArena Corporate Results Monitor. Today's Reports:...

ASX healthcare stocks showed mixed results following the release of their most recent financials on Tuesday. Three companies in particular stand out, with two finishing in the green and one in the red. Integral Diagnostics Ltd (ASX: I...

You'll find that not everyone's definition of top ASX stocks is the same. Some investors prefer lower-risk blue-chip stocks, while others are willing to take a punt on higher-risk small-cap growth shares. And, of course, passive income inve...

ASX health stocks rise 0.8% past five days as broader market lifts 3.7%  Morgans says ProMedicus ‘produced yet another record result’ with net profit of $82.8m in FY24  CSL falls on FY24 results but Morgans still bullish on ASX’s largest h...

Neurotech to secure one or more strategic partnerships for NTI164 in the US, Europe and Asia Partnerships aim to support clinical, regulatory development, manufacturing and future market launches of NTI164 Neurotech to pursue multiple regi...

The Australian Securities Exchange (ASX) has started this week on a much more positive note compared to last week as investors eagerly await earnings from some of the ASX’s biggest companies.  The S&P/ASX200 rallied 58.1 points to 7,...

The ASX200 closed up 1.25% at 7777.7 points, completing the second green session in a row. It has been a volatile time, and the market has finished the week by clawing back some, but not all, losses from the previous 5 sessions. China...

While the S&P/ASX 200 Index (ASX: XJO) is enjoying a strong session on Friday, up 1.45% to 7,792.6 points, several ASX shares are struggling to keep pace. Here’s a look at four companies experiencing declines today and the reasons behin...

The Australian Securities Exchange (ASX) has rounded out a volatile week in the positive, with the S&P/ASX200 advancing 95.70 points, or 1.3%, to 7,777.70 on Friday (9 August). The index rose above its 125-day moving average and all...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very positive note. At the time of writing, the benchmark index is up 1.45% to 7,792.6 points. Four ASX shares that have failed to follow the market...

Neuren (ASX:NEU) was the biggest faller in lunchtime trades on Friday after announcing some children were “minimally improved” in phase 2 of a trial treating children with Angelman syndrome. Shares were down -6.2% to just above $16.00ea...

Neuren shows promise in Angelman drug but shares down 7pc Avita aims for profitability by Q3 FY25 IDT lands $2.5-$4m mRNA contract with Sanofi   Neuren’s Angelman drug shows promise Market darling Neuren Pharmaceuticals (ASX:NEU) has just...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares have returned from their trading halt with an almighty thud. In morning trade, the pharmaceuticals company's shares are down 9% to $15.51. This compares unfavourably to the performance of the ASX...

The S&P/ASX 200 Index (ASX: XJO) comprises 11 market sectors, and the outperformer over the past decade may surprise you. It's not the flashy tech sector, nor the sectors home to the mega-miners or the Big Four bank shares. I...

With recent market volatility, prudent investors in ASX shares may be finding some relief. The uncertainty ahead, however, leaves many questioning what to expect next. While some retail investors have faced challenges, large institutional i...

Prudent investors in ASX shares will no doubt be breathing easier on Wednesday following the recent market volatility. However, visibility on what's next is not clear. It was Roman author Pliny the Elder who wrote "In wine, there is trut...

As the market whipsaws away this week, one ASX 200 healthcare share is on ice on Wednesday. Neuren Pharmaceuticals Ltd (ASX: NEU) requested the trading halt pending an announcement on one of its clinical programs. The business also r...

If you want to give your portfolio a boost, then it could be worth looking at Neuren Pharmaceuticals Ltd (ASX: NEU) shares. That's because one leading broker is tipping the ASX stock to rise over 60% from current levels. What is the broker...

Recent evaluations have spotlighted three ASX 200 shares that present notable opportunities for investors seeking substantial returns. These shares are garnering significant interest due to their strong growth potential and strategic positi...

Brokers have been running the rule over a large number of ASX 200 shares in recent weeks. Three shares that are highly rated and feature on best idea lists are named below. Here's why they could be great options: Neuren Pharmaceuticals Ltd...

  Neurotech reports positive results from extension phase of Phase 1/2 trial of NTI164 to treat Rett Syndrome NTI164 is first broad-spectrum cannabinoid drug therapy to show significant clinical improvement in Rett Syndrome patients All 14...

ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update  Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

Neuren’s NNZ-2591 receives a Rare Pediatric Disease Designation from US FDA This could lead to a Priority Review Voucher if drug is approved Neuren is also preparing for a key FDA meeting, building on positive trial results    Neuren Phar...

The S&P/ASX 200 Index (ASX: XJO) enjoyed another strong session this Wednesday, ploughing further into 8,000-point territory and resetting its all-time record...

Following Monday's market euphoria and fresh all-time highs, it was only natural for the S&P/ASX 200 Index (ASX: XJO) to experience a bit of a correction on Tuesday. Indeed, that's precisely what transpired, with the ASX 200 slipping by...

After yesterday's market euphoria and fresh all-time highs, it was only natural that the S&P/ASX 200 Index (ASX: XJO) endured a bit of a jolt back to earth this...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

Fortunately for growth investors, there are a lot of quality options for them to choose from on the Australian share market. Two ASX 200 growth shares that have been rated as top buys by brokers are listed below. Here's what they are saying...